PAOG Engages Goldman Small Cap Research For Analyst Coverage
05 August 2020 - 2:32AM
InvestorsHub NewsWire
Sandusky, OH -- August 4, 2020 --
InvestorsHub NewsWire -- PAO Group, Inc. (USOTC:
PAOG) today announced engaging Goldman Small Cap Research to
provide ongoing analyst coverage. PAOG recently executed a
management takeover followed by the acquisition of a cannabis
cultivation operation and cannabis extract biopharmaceutical
asset. The company is currently updating its web presence and
public disclosures and has now engaged Goldman Small Cap Research
to provide analyst coverage on the company’s strategy, operations
and assets. An initial report is anticipated next week.
Goldman Small Cap Reseach has recently covered
PETV,
CBDL, and
PLIN.
See https://www.goldmanresearch.com/.
www.paogroupinc.com.
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
CBD Life Sciences (PK) (USOTC:CBDL)
Historical Stock Chart
From Oct 2024 to Nov 2024
CBD Life Sciences (PK) (USOTC:CBDL)
Historical Stock Chart
From Nov 2023 to Nov 2024